OT: What changes are you and family making to your lifestyle due to coranavirus?
- Thread starter Kitaman
- Start date
Dream Jobbed 2.0
“Most definitely”
- Joined
- May 3, 2016
- Messages
- 15,122
- Reaction Score
- 57,289
4th straight drop in cases yesterday. Hard to attribute it to anything other than holiday/bad weather across most of the country shutting down drive through testing.
storrsroars
Exiled in Pittsburgh
- Joined
- Mar 23, 2012
- Messages
- 23,013
- Reaction Score
- 55,702
Do you know for sure that fewer trees fell just because no one heard them?
- Joined
- Aug 28, 2011
- Messages
- 29,252
- Reaction Score
- 82,103
.-.
Dream Jobbed 2.0
“Most definitely”
- Joined
- May 3, 2016
- Messages
- 15,122
- Reaction Score
- 57,289
ctchamps
We are UConn!! 6 >>>1!
- Joined
- Aug 24, 2011
- Messages
- 17,790
- Reaction Score
- 45,797
Emory University is conducting a study on remdesivir. It's a double blind study (the largest in the world for this drug) with results to be reported in about a week. The head of the study does not know who received a placebo and who received remdesivir but he stated that a number of patients have a reduction in the duration of infection. It's obvious he believes those patients are getting remdesivir even if he can't state it. If these people have antibodies against the virus then we have a treatment for at least some portion of the population.
Brazil just discontinued a study on Hydroxychloroquine/Azithromycin after concluding there is no benefit to patients. Some people in the Emory hospital are refusing to partake in the trial insisting on the antimalarial modality of treatment. I'll wait for the studies conducted by WHO and the CDC to determine if the antimalarial treatment is effective or not. Humanity is desperate for something but these medicines are not absolutely safe. If they are indeed ineffective we could be killing an equal percentage of people with indiscriminate usage of the antimalarial medications as the Coronid-19 virus.
In the best of times there are problems with medications and not all of those problems were the result of graft. Under current conditions we can expect hysteria to increase the chances of problems. That certainly doesn't mean that everyone pursuing a treatment is corrupt. There is validity behind the majority of the scientific communities reluctance to give the green light to any of these proposed solutions without at least some study. The compromise is the choice to allow promising studies to fast track without further studies to determine if the treatment is worse than the disease.
- Joined
- May 14, 2016
- Messages
- 732
- Reaction Score
- 976
Look into Gilead. Right now remdesivir is compassionate use but if it’s approved and this is long-term, this could be a good buy.
Happy Birthday 88 hope you have a great day, considering the current events.
Unlike the rest of the economy??
- Joined
- Sep 16, 2011
- Messages
- 55,747
- Reaction Score
- 210,006
I've held Gilead for over a month, it hasn't done anything.
.-.
Are you being intentionally obtuse?
You asked why the hospitals are asking for the feds to help with supplies. Their revenues have been drastically slashed, they are the very definition of essential services, and they have to make payroll, procure supplies, and continue to operate.
Are you living in an alternate reality where only the hospitals have asked the Federal and/or State government for help?
- Joined
- Aug 25, 2011
- Messages
- 17,151
- Reaction Score
- 36,069
How long will our food supply (meats/vegetables) last without higher prices or even worse, shortages?
I know short term we're ok, but this could become a big issue.
I'm considering buying a freezer, and my wife is actually frightened. Hell she is even buying spam and other canned meat now. I wished she would stay away from the TV (i.e. news).
I know short term we're ok, but this could become a big issue.
I'm considering buying a freezer, and my wife is actually frightened. Hell she is even buying spam and other canned meat now. I wished she would stay away from the TV (i.e. news).
- Joined
- Feb 18, 2012
- Messages
- 1,598
- Reaction Score
- 3,838
Check out the garden thread. Some good advice.
- Joined
- Feb 18, 2012
- Messages
- 1,598
- Reaction Score
- 3,838
There’s Been a Spike in People Dying at Home in Several Cities. That Suggests Coronavirus Deaths Are Higher Than Reported. — ProPublica
Coronavirus death counts are based on positive tests and driven by hospital deaths. But data from major metropolitan areas shows a spike in at-home deaths, prompting one expert to say current numbers were just “the tip of the iceberg.”
Dream Jobbed 2.0
“Most definitely”
- Joined
- May 3, 2016
- Messages
- 15,122
- Reaction Score
- 57,289
More and more outlets (including the Today Show) have picked up on the meat shortage news. Even if there’s no meat shortage there will be
.-.
- Joined
- Sep 16, 2011
- Messages
- 55,747
- Reaction Score
- 210,006
Yes they are, old folks are the ones dying.The old folks in the USA aren't the ones threatened as once thought. This is sobering info.
- Joined
- Aug 25, 2011
- Messages
- 17,151
- Reaction Score
- 36,069
Yeah that's true, but in respect to social distancing this is sobering news for the 'invincible' population.
Husky25
Dink & Dunk beat the Greatest Show on Turf.
- Joined
- Sep 10, 2012
- Messages
- 18,999
- Reaction Score
- 20,194
They are going to start another (probably needless) run. The news needs ratings and the worst case scenario draws more eyeballs than likely scenarios. Discriminating people understand what is news and what is for effect but also need to keep an eye on the Chicken Littles' reactions.
- Joined
- Aug 25, 2011
- Messages
- 17,151
- Reaction Score
- 36,069
Yeah I posted the news story above because my wife is one of those people (chicken littles).
.-.
In experimental treatments, Connecticut hospitals are using blood plasma from recovered coronavirus patients to help those who are still sick
Medical professionals are beginning trials and experimental treatments that involve taking blood plasma — which is the fluid component of blood — from recovered coronavirus patients and infusing it into the bloodstreams of severely ill patients. The plasma from the recovered patients contains antibodies, which help the human body fight pathogens such as bacteria and viruses.
While still unproven on a large scale, the theory is that a recovered COVID-19 patient’s antibodies should also help fight the disease in patients who are still sick.
“If you can take that same plasma and infuse it into a patient that’s in the ICU or really compromised, you can fight the infection with the antibodies from the [plasma],” said Dr. Justin Lundbye, chief medical officer at Waterbury Hospital. “Those antibodies will then go after the virus and kill it.”
Trinity Health was the first hospital system with Connecticut locations to begin a clinical trial using the plasma therapy, although Yale New Haven Health is applying for approval of a trial. The Yale New Haven Health, Nuvance Health and Hartford HealthCare systems are also using blood plasma in a more traditional, non-trial setting.
A number of hospitals across the state, including the Hartford HealthCare and Yale New Haven Health systems, are gearing up to provide convalescent plasma transfusions outside of the scope of a clinical trial, in a less rigorous program that the FDA refers to as “expanded access.” (In the meantime, Yale New Haven Health is also applying to conduct its own clinical trial.)
Although medical professionals around the world are now studying convalescent plasma, they have not yet proven whether it’s effective in treating COVID-19.
However, both Hussain, of Trinity Health, and Dr. Mahalia Desruisseaux of Yale New Haven Health pointed to promising results out of a small Chinese study of five critically ill COVID-19 patients. In that study, three of the patients were released from the hospital and two were stabilized after convalescent plasma treatment.
Another Chinese study showed similar results but was again very small, with only 10 patients.
Hussain also pointed to the track record of convalescent plasma in fighting other viral epidemics, from before COVID-19 came on the scene. When treated with convalescent plasma, patients had a better chance of beating Ebola, H1N1 and SARS, previous studies have found.
Trinity Health was one of the first four health systems in the U.S. to gain approval for a clinical trial of convalescent plasma. The health system has hospitals across Connecticut and Massachusetts, including St. Francis Hospital and Medical Center in Hartford and Mercy Medical Center in Springfield.
Hussain said the health system rushed to apply for a clinical trial after reading about the five-patient study in China. The study was small and didn’t have a comparison group, but Hussain said the results were attention-grabbing nonetheless.
“It’s amazing that [three patients] were able to go home,” Hussain said. “We thought, ‘We need to look into this and see what we can give our patients.’ ”
The hospital system is already using other treatments, such as hydroxychloroquine, for moderately ill patients, but there currently is no viable treatment for severely ill patients, Hussain said. So Trinity Health decided to target severely ill patients with the convalescent plasma trial.
“There isn’t really anything out there that we’re using for severe disease," Hussain said.
Dr. Latha Dulipsingh of St. Francis said on Thursday that the Trinity Health system hopes to give the first convalescent plasma transfusion by late this week. Dulipsingh said the hospital system will share results once it has enrolled 10 to 15 patients.
But Hussain said the health system will enroll as many patients as possible, in order to strengthen the study’s statistical analysis. He estimated the health system should be able to release data in about a month. The study will focus mainly on whether the treatment increases patients’ chances of survival.
“The primary outcome definitely is mortality,” Hussain said. “We want to make sure we’re able to save these patients.”
In lieu of clinical trials, some hospitals are using convalescent plasma under a protocol that the FDA dubs “expanded access." This approach, more similar to the typical in-patient treatment process, does not come with many of the requirements of a more formal clinical trial and is designed for patients who cannot participate in trials.
Under the expanded access protocol, only the most severely ill COVID-19 patients can be treated with convalescent plasma. Desruisseaux, at Yale New Haven Health, said some patients who are not yet critically ill may also be treated, if their doctors determine that they will soon become critically ill.
The Hartford HealthCare, Nuvance Health and Yale New Haven Health systems are gearing up to administer convalescent plasma under this protocol. The systems are receiving blood plasma from partner blood centers, such as the Rhode Island Blood Center and the American Red Cross.
The Yale New Haven Health system was scheduled to receive its first convalescent plasma unit on Tuesday morning, according to Tormey. Nuvance Health, which includes Danbury and Norwalk hospitals, has said it is recruiting a program that will start later this month. And Hartford HealthCare’s Dr. Ajay Kumar said the convalescent plasma program has not yet started in the hospital system, but “will begin as soon as we identify the patients.”
Medical professionals are beginning trials and experimental treatments that involve taking blood plasma — which is the fluid component of blood — from recovered coronavirus patients and infusing it into the bloodstreams of severely ill patients. The plasma from the recovered patients contains antibodies, which help the human body fight pathogens such as bacteria and viruses.
While still unproven on a large scale, the theory is that a recovered COVID-19 patient’s antibodies should also help fight the disease in patients who are still sick.
“If you can take that same plasma and infuse it into a patient that’s in the ICU or really compromised, you can fight the infection with the antibodies from the [plasma],” said Dr. Justin Lundbye, chief medical officer at Waterbury Hospital. “Those antibodies will then go after the virus and kill it.”
Trinity Health was the first hospital system with Connecticut locations to begin a clinical trial using the plasma therapy, although Yale New Haven Health is applying for approval of a trial. The Yale New Haven Health, Nuvance Health and Hartford HealthCare systems are also using blood plasma in a more traditional, non-trial setting.
A number of hospitals across the state, including the Hartford HealthCare and Yale New Haven Health systems, are gearing up to provide convalescent plasma transfusions outside of the scope of a clinical trial, in a less rigorous program that the FDA refers to as “expanded access.” (In the meantime, Yale New Haven Health is also applying to conduct its own clinical trial.)
Although medical professionals around the world are now studying convalescent plasma, they have not yet proven whether it’s effective in treating COVID-19.
However, both Hussain, of Trinity Health, and Dr. Mahalia Desruisseaux of Yale New Haven Health pointed to promising results out of a small Chinese study of five critically ill COVID-19 patients. In that study, three of the patients were released from the hospital and two were stabilized after convalescent plasma treatment.
Another Chinese study showed similar results but was again very small, with only 10 patients.
Hussain also pointed to the track record of convalescent plasma in fighting other viral epidemics, from before COVID-19 came on the scene. When treated with convalescent plasma, patients had a better chance of beating Ebola, H1N1 and SARS, previous studies have found.
Trinity Health was one of the first four health systems in the U.S. to gain approval for a clinical trial of convalescent plasma. The health system has hospitals across Connecticut and Massachusetts, including St. Francis Hospital and Medical Center in Hartford and Mercy Medical Center in Springfield.
Hussain said the health system rushed to apply for a clinical trial after reading about the five-patient study in China. The study was small and didn’t have a comparison group, but Hussain said the results were attention-grabbing nonetheless.
“It’s amazing that [three patients] were able to go home,” Hussain said. “We thought, ‘We need to look into this and see what we can give our patients.’ ”
The hospital system is already using other treatments, such as hydroxychloroquine, for moderately ill patients, but there currently is no viable treatment for severely ill patients, Hussain said. So Trinity Health decided to target severely ill patients with the convalescent plasma trial.
“There isn’t really anything out there that we’re using for severe disease," Hussain said.
Dr. Latha Dulipsingh of St. Francis said on Thursday that the Trinity Health system hopes to give the first convalescent plasma transfusion by late this week. Dulipsingh said the hospital system will share results once it has enrolled 10 to 15 patients.
But Hussain said the health system will enroll as many patients as possible, in order to strengthen the study’s statistical analysis. He estimated the health system should be able to release data in about a month. The study will focus mainly on whether the treatment increases patients’ chances of survival.
“The primary outcome definitely is mortality,” Hussain said. “We want to make sure we’re able to save these patients.”
In lieu of clinical trials, some hospitals are using convalescent plasma under a protocol that the FDA dubs “expanded access." This approach, more similar to the typical in-patient treatment process, does not come with many of the requirements of a more formal clinical trial and is designed for patients who cannot participate in trials.
Under the expanded access protocol, only the most severely ill COVID-19 patients can be treated with convalescent plasma. Desruisseaux, at Yale New Haven Health, said some patients who are not yet critically ill may also be treated, if their doctors determine that they will soon become critically ill.
The Hartford HealthCare, Nuvance Health and Yale New Haven Health systems are gearing up to administer convalescent plasma under this protocol. The systems are receiving blood plasma from partner blood centers, such as the Rhode Island Blood Center and the American Red Cross.
The Yale New Haven Health system was scheduled to receive its first convalescent plasma unit on Tuesday morning, according to Tormey. Nuvance Health, which includes Danbury and Norwalk hospitals, has said it is recruiting a program that will start later this month. And Hartford HealthCare’s Dr. Ajay Kumar said the convalescent plasma program has not yet started in the hospital system, but “will begin as soon as we identify the patients.”